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Cdc6 degradation requires phosphodegron 
created by GSK-3 and Cdk1 for SCFCdc4 
recognition in Saccharomyces cerevisiae
Amr Al-Zain, Lea Schroeder, Alina Sheglov, and Amy E. Ikui
Department of Biology, Brooklyn College, City University of New York, Brooklyn, NY 11210
ABSTRACT To ensure genome integrity, DNA replication takes place only once per cell cycle 
and is tightly controlled by cyclin-dependent kinase (Cdk1). Cdc6p is part of the prereplica-
tive complex, which is essential for DNA replication. Cdc6 is phosphorylated by cyclin-Cdk1 
to promote its degradation after origin firing to prevent DNA rereplication. We previously 
showed that a yeast GSK-3 homologue, Mck1 kinase, promotes Cdc6 degradation in a 
SCFCdc4-dependent manner, therefore preventing rereplication. Here we present evidence 
that Mck1 directly phosphorylates a GSK-3 consensus site in the C-terminus of Cdc6. The 
Mck1-dependent Cdc6 phosphorylation required priming by cyclin/Cdk1 at an adjacent CDK 
consensus site. The sequential phosphorylation by Mck1 and Clb2/Cdk1 generated a Cdc4 E3 
ubiquitin ligase–binding motif to promote Cdc6 degradation during mitosis. We further re-
vealed that Cdc6 degradation triggered by Mck1 kinase was enhanced upon DNA damage 
caused by the alkylating agent methyl methanesulfonate and that the resulting degradation 
was mediated through Cdc4. Thus, Mck1 kinase ensures proper DNA replication, prevents 
DNA damage, and maintains genome integrity by inhibiting Cdc6.
INTRODUCTION
Initiation of DNA replication requires prior assembly of the prerepli-
cative complex (pre-RC) by Cdc6- and Cdt1-dependent recruitment 
of the minichromosome maintenance complex (Mcm2–7) to the or-
igin-bound origin recognition complex (Orc1-6) (Araki, 2010). Pre-
RC assembly licenses the origin to further recruit the Dbf4-kinase/
Cdc7 complex to form a bidirectional replication fork (Araki, 2010). 
DNA synthesis then occurs through the activity of S-phase/mitotic 
cyclin-Cdk complexes (Tanaka et al., 2007; Zegerman and Diffley, 
2007). In Saccharomyces cerevisiae, this includes six B-type cyclins 
(Clb1–6) and one Cdk1 (Cdc28p) (Nasmyth, 1996).
Cells ensure that DNA replication occurs only once per cell cycle 
in order to maintain genome integrity. To achieve this, the pre-RC is 
rapidly disassembled after Cdk1-dependent phosphorylation, and 
reassembly is inhibited until the following cell cycle. The inhibition 
of pre-RC assembly is dependent on B-type cyclins (Dahmann et al., 
1995; Ikui et al., 2007) and involves multiple overlapping mecha-
nisms. Mcm2–7 is excluded from the nucleus after phosphorylation 
by the cyclin-Cdk complex (Labib et al., 1999; Nguyen et al., 2000). 
Orc2 and Orc6 are phosphorylated to inhibit pre-RC loading 
(Nguyen et al., 2001). To further prevent pre-RC assembly, Clb2 
binds to the phosphorylated N-terminal domain of Cdc6 (Mimura 
et al., 2004), and Clb5p binds to the Arg-X-Leu (RXL) domain in 
Orc6 to sterically inhibit Cdt1/Mcm2–7 loading (Chen and Bell, 
2011; Wilmes et al., 2004). In addition, Cdc6p levels are tightly reg-
ulated during the cell cycle. Cdc6 is transcribed in late mitosis and 
G1 and accumulates throughout G1; then its levels rapidly drop af-
ter passage through START (Piatti et al., 1995; Zwerschke et al., 
1994). Cdc6 is also regulated through its localization (Honey and 
Futcher, 2007).
Multiple mutations affect rereplication control, including 
mutation of Orc2 and Orc6 phosphorylation sites (ORC2-ps and 
ORC6-ps) (Nguyen et al., 2001), forced nuclear localization of 
Mcm2–7 (MCM7-NLS) (Nguyen et al., 2000), and stabilization 
through N-terminal truncation of Cdc6p (CDC6ΔNT) (Drury et al., 
1997). Combining these mutations is lethal and induces rereplica-
tion (Nguyen et al., 2001; Wilmes et al., 2004; Archambault et al., 
2005). In addition, each of these individual mutations strongly 
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(Figure 1A). We mutated each amino acid from Thr, Ser, or Pro in the 
GSK-3 consensus site to Ala and examined the stability of Cdc6p. 
Wild-type Cdc6p was degraded after expression was shut off during 
mitosis (Figure 1B; Drury et al., 1997, 2000; Perkins et al., 2001). 
Cdc6-T368A, P369A, S372A, and P373A single mutants or T368A-
S372A double-mutant proteins were stabilized, as was Cdc6p in 
mck1-deletion cells, indicating that the GSK consensus sequence 
from T368 to S372 is crucial for Cdc6 degradation (Figure 1B; 
Perkins et al., 2001). Cdc6 stabilization by P369A or P373A mutation 
indicates that T368 or S372 might be potential Cdk1 phosphoryla-
tion sites. A single mutation in Cdc6 at the N-terminus, T39A or 
S43A, did not alter Cdc6p stability during mitosis (Figure 1B). How-
ever, we observed high Cdc6p protein levels at time zero when the 
two mutations at the GSK-3 consensus sites T39A and T368A were 
combined (Figure 1B). Consistent with Cdc6 protein stability in 
CDC6-T39A, T368A double mutations (Figure 1B), we found that 
GAL-CDC6-T39A, T368A cells showed elongated bud and mitotic 
arrest (Figure 1D and Supplemental Figure S1). We also observed 
more stabilized Cdc6p in CDC6-T368A or CDC6-T39A, T368A cells 
than in Δmck1 cells (Figure 1B). This indicates that Cdc6-T368 site is 
phosphorylated by multiple kinases.
We previously found that mck1 deletion is synthetically lethal 
with an ORC6-rxl mutation that disrupts a control for DNA rereplica-
tion (Ikui et al., 2012). Given the Cdc6p stabilization in mck1-deletion 
cells (Figure 1B), we tested whether the CDC6 GSK-3 consensus-site 
mutations that stabilized Cdc6p also induce enhanced synthetic 
lethality in the ORC6-rxl mutant. Viability of yeast cells that contain 
various CDC6 mutations and the ORC6-rxl mutation were tested. 
The GAL-CDC6 ORC6-rxl mutant caused increased lethality on ga-
lactose-containing plates compared with controls (Figure 1C). The 
lethality was exacerbated when cells contained CDC6 mutations 
(T368A, P369A, S372A, and P373A single mutants or T368A and 
S372A double mutants) at the GSK-3 consensus sites (Figure 1C, 
top). ORC6-rxl GAL-CDC6-T39A, T368A cells showed enhanced 
lethality compared with ORC6-rxl GAL-CDC6-T39A or ORC6-rxl 
GAL-CDC6-T368A (Figure 1C, bottom). Next the CDC6-T368A 
mutation was integrated into the genome locus and was crossed 
with the ORC6-rxl and ORC6-rxl,ps mutants. The resulting double 
mutants, ORC6-rxl CDC6-T368A and ORC6-rxl,ps CDC6-T368A, 
showed slow growth (Supplemental Figure S2).
Mck1 phosphorylates Thr-368 in Cdc6 after priming 
by Clb2/Cdk1
To identify the Cdk1 or Mck1 phosphorylation sites on Cdc6, we 
performed an in vitro kinase assay using various Cdc6 synthetic pep-
tides with Mck1p kinase or Cdk1p kinase purified from yeast. Clb2/
Cdk1 phosphorylated the wild-type Cdc6 synthetic peptide con-
taining the C-terminal GSK-3 consensus site; however, the phos-
phorylation was abolished when the Cdc6 peptide contained a 
phosphate at S372 (Figure 2A, left). This indicates that Clb2/Cdk1 
targets the S372 site but not the T368 site. On the other hand, Mck1 
did not phosphorylate the wild-type Cdc6 peptide unless the pep-
tide contained a phosphate at S372 (Figure 2A, left). The Mck1-
dependent Cdc6 phosphorylation was abolished when we used 
Cdc6 peptides that contained an alanine mutation at T368 (Figure 
2A, left). This result proved that Cdc6-T368 is phosphorylated by 
Mck1 in vitro. Mck1 weakly phosphorylated the Cdc6 peptide that 
contained the N-terminal GSK-3 consensus site at T39. However, 
the phosphorylation efficiency was ∼20-fold less than that at the 
C-terminal T368 (Figure 2A, right). Clb2/Cdk1 did not phosphory-
late the Cdc6 peptide that contained the Cdk1 consensus site at 
T39 and S43 (Figure 2A, right).
synergizes with ORC6 mutation at the RXL domain (ORC6-rxl) 
(Wilmes et al., 2004). For instance, an ORC6-rxl CDC6ΔNT double 
mutant causes slow growth and increases the frequency of rereplica-
tion, with the functional outcome of causing DNA damage and acti-
vating the DNA damage checkpoint (Archambault et al., 2005; Ikui 
et al., 2007).
We previously found that the ORC6-rxl mutation is syntheti-
cally lethal with the deletion of the MCK1 gene, a yeast homo-
logue of glycogen synthase kinase 3 (GSK-3) (Archambault et al., 
2005; Ikui et al., 2012). Meiosis and centromere regulatory kinase 
(Mck1) is a serine/threonine kinase whose catalytic activity re-
quires autophosphorylation on tyrosine residues (Lim et al., 1993; 
Brazill et al., 1997; Rayner et al., 2002). Mck1p was first found 
as a dosage suppressor of a centromere mutation that causes 
chromosomal missegregation (Shero and Hieter, 1991) and as an 
early regulator of genes required for meiosis and sporulation 
(Neigeborn and Mitchell, 1991). In addition, it is involved in the 
stress response by promoting the binding of transcription factors 
to the promoters of stress-responsive genes (Hirata et al., 2003). 
Accordingly, mck1-deletion cells are hot and cold sensitive and 
sensitive to the microtubule-destabilizing drug benomyl (Shero 
and Hieter, 1991; Andoh et al., 2000). Mck1 has a function in pro-
tein degradation; during heat stress, it promotes Rog1 degrada-
tion through the ubiquitin-ligase Rsp5 (Andoh et al., 2000). Mck1 
also has a role in cell cycle regulation. It is a downstream regula-
tor of calcineurin signaling that promotes ubiquitin-mediated 
Hsl1 degradation (Mizunuma et al., 2001) and Rcn1 degradation 
(Kishi et al., 2007). Mck1 also phosphorylates the sister cohesion 
protein Eco1, after Dbf4-kinase/Cdc7 and Cdk1-dependent 
priming phosphorylation, for ubiquitin-mediated degradation 
(Lyons et al., 2013).
There are eight CDK consensus sites in the N- and C-termini of 
Cdc6 that target Cdc6 for ubiquitin-mediated proteolysis (Drury 
et al., 1997, 2000; Elsasser et al., 1999; Perkins et al., 2001). In mito-
sis, Cdc6p is degraded through the SCFCdc4 ubiquitin ligase, which 
is dependent on Cdc6 T368 and S372 (Drury et al., 1997, 2000). 
Previously, we elucidated a novel function of Mck1 for DNA rerepli-
cation inhibition (Ikui et al., 2012). We found that Mck1 promotes 
Cdc6 degradation in a SCFCdc4-dependent manner through the C-
terminus. The C-terminal residues 368TPTTSP372 in Cdc6 contain a 
GSK-3 consensus site in the form S/TxxxS/Tp. Theoretically, GSK-3 
kinase phosphorylates the first S/T after the priming phosphoryla-
tion of the S/T residue at the fourth position by another kinase (Fiol 
et al., 1987). T368 and S372, which are important for Cdc6 degrada-
tion during mitosis, have been studied as putative Cdk1 phosphory-
lation sites (Drury et al., 2000).
In this article, we provide evidence in vitro and in vivo that 
Mck1, but not Cdk1, phosphorylates T368 only after priming phos-
phorylation of S372 by Clb2-Cdk1 to promote Cdc6 degradation 
during mitosis. The Cdc6 phosphodegron created by Cdk1 and 
Mck1 is crucial for Cdc4 binding to promote Cdc6 degradation. 
We also show that GSK3-dependent Cdc6 degradation is aug-
mented after DNA damage stress in order to maintain genome 
integrity.
RESULTS
GSK-3 consensus site at T368-S372 in Cdc6 is responsible 
for Cdc6 degradation
The GSK-3 consensus motif contains S/T-x-x-x-S/T. There are two 
GSK-3 consensus sites in Cdc6, one at each terminus (Figure 1A). 
The TPTTS GSK-3 consensus site (T368 to S372) in Cdc6 is over-
lapped with two CDK sites at TP (368 and 369) and SP (372 and 373) 
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FIGURE 1: Analysis of GSK-3 consensus sites in Cdc6. (A) Cdc6 contains two GSK-3 consensus sites, which overlap with 
two CDK consensus sites. (B) GAL-CDC6-HA strains with various mutations (T368A, P369A, S372A, P373A, T39A, S43A, 
T39A-T368A, and T368A-S372A) were expressed with galactose-containing medium for 2 h and then blocked with 
nocodazole for 2 h. Cdc6 expression was then suppressed by adding glucose. Protein extracts were collected every 
5 min and subjected to Western blot analysis to observe Cdc6-HA. Pgk1 was used as a loading control. GAL-CDC6-HA 
in mck1-deletion cells was examined using the same method. Western blotting images for WT, Δmck1, CDC6-T39A, 
CDC6-T368A, and CDC6-T39A,T368A were quantified. Percentage of Cdc6 protein remaining relative to time zero is 
shown. Results are the average of three independent experiment, and error bars indicate SD. *p < 0.05. (C) Strains with 
the indicated genotypes were serially diluted 10-fold, plated on yeast extract/peptone/dextrose or yeast extract/
peptone/galactose plates, and incubated at 30°C for 2 d. (D) GAL-CDC6, GAL-CDC6-T368A, or GAL-CDC6-T39A-T368A 
was grown in raffinose-containing medium first. Cdc6p was expressed with galactose for 3 h.
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Next we tested whether Mck1 kinase 
phosphorylates Cdc6-T368 in vivo, using a 
phosphospecific antibody against the T368 
site. Cdc6 was phosphorylated at the T368 
site in wild-type cells when the cell cycle was 
arrested during mitosis using nocodazole 
(Figure 2B, left). The Cdc6-T368 phosphory-
lation was abolished in the Cdc6-T368A mu-
tant as well as in Δmck1 cells. We did not 
detect T368 phosphorylation when the 
priming site at S372 was mutated to alanine, 
indicating that Mck1 phosphorylates T368 
only when the S372 priming site is phos-
phorylated (Figure 2B, left). Furthermore, 
the T368 site was not phosphorylated in 
wild-type cells arrested in G1 phase with α-
factor (Figure 2B, right). These results sup-
port our priming model (Ikui et al., 2012) 
that Cdc6 requires Cdk1-dependent prim-
ing at S372 in order to be phosphorylated 
by Mck1 at T368 during mitosis.
We next tested the cyclin dependence of 
Mck1-induced Cdc6 phosphorylation at 
T368. The phosphorylation status of Cdc6-
T368 was analyzed in vivo in GAL-CDC6, 
Δclb2 GAL-CDC6, Δclb4 GAL-CDC6 or 
Δclb5 GAL-CDC6 cells during mitosis. 
Cdc6-T368 phosphorylation was depen-
dent on the mitotic cyclin Clb2 (Figure 2C), 
which is consistent with our in vitro kinase 
assay results. The phosphorylation was also 
dependent on the S-phase cyclin Clb5. 
However, the phosphorylation was still ob-
served in clb4-deletion cells (Figure 2C).
Cdc6 phosphorylation by Mck1 and 
Cdk1 creates a Cdc4 phosphodegron
We previously proposed a model in which 
double phosphorylation of Cdc6 by Mck1 
and Cdk1 may create a phosphodegron that 
is recognized by Cdc4 (Ikui et al., 2012). To 
test this, we created a GAL-CDC6-Δ370 mu-
tant strain lacking one amino acid between 
the Mck1 and Cdk1 phosphorylation sites 
and whose expression is controlled under 
the GAL promoter. Similar to wild-type 
Cdc6p, the Cdc6-Δ370 protein was still de-
gradable after glucose addition, whereas 
the Cdc6-Δ370Δ371 protein, lacking two of 
the three amino acids of the phosphode-
gron, was more stable than both single mu-
tants (Figure 3A). Cdc6-T370A or Cdc6-
T371A proteins were also degraded, 
signifying that spacing and not the specific 
FIGURE 2: Mck1 phosphorylates the T368 site in Cdc6 after priming by Clb2-Cdk1. (A) To 
measure Clb2-Cdk1 and Mck1 kinase activities on Cdc6 phosphopeptides, various synthetic 
peptides of Cdc6 (residues 36–47 or 365–376; shown above) were incubated with purified 
kinases from asynchronous yeast cultures and [γ-32P]ATP. For each kinase, phosphate 
incorporation was normalized to a control reaction without peptides. Values for the C-terminal 
peptides represent the average from three independent experiments. Error bars represent SD. 
(B) Indicated strains were grown in raffinose-containing medium first. Cdc6 expression was 
induced with galactose for 2 h. Cells were blocked with nocodazole or α-factor for 2 h. Western 
blotting was performed using anti–phosphoT368 of Cdc6, anti-HA, anti-Pgk1, and anti-Clb2 
antibodies, respectively. (C) Indicated strains were grown in raffinose-containing medium first, 
and then galactose was added to induce Cdc6 expression for 2 h. Cells were blocked with 
nocodazole for 2 h. Western blotting was performed using anti–phosphoT368 of Cdc6, anti-HA, 
and anti-Pgk1 antibodies, respectively (left). Band intensity for the phospho-Cdc6-T368 was 
quantified and normalized to the total 
amount of Cdc6 (right). The ratio 
phospho-T368/total Cdc6 in Δclb4 was set 
as 1. Results are the average of three 
independent experiments; error bars 
indicate SD.
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(Figure 3B, bottom). We conclude that Cdc4 binds to the Cdc6 
phosphodegron at T368 and S372 when there are two or three 
amino acids between phosphorylations. Only one amino acid be-
tween phosphorylations (Cdc6-Δ370Δ371) causes stability because 
Cdc4 does not recognize it. T368M mutant was used as a negative 
control (Perkins et al., 2001).
Cdc6 degradation upon DNA damage is mediated by Mck1
It has been shown that the DNA alkylating agent methyl methane-
sulfonate (MMS) triggers Cdc6 degradation in S. cerevisiae 
amino acid sequence of 370 and 371 is critical for recognition, po-
tentially by Cdc4 (Figure 3A). To determine whether Cdc4 binds to 
Cdc6 with specific spacing between the two phosphorylations at 
T368 and S372, we tested the binding efficiency between Cdc4 and 
Cdc6 by a yeast two-hybrid assay. Consistent with the stabilization 
data, Cdc4 did not bind to Cdc6-Δ370Δ371 (Figure 3B). However, 
Cdc4 recognized wild-type Cdc6 and Cdc6-Δ370 (Figure 3B). Each 
LexA-Cdc6 fusion protein was expressed at comparative levels, and 
therefore the protein-binding defect between Cdc4 and Cdc6 in the 
Cdc6-Δ370Δ371 mutant is not due to poor protein expression levels 
FIGURE 3: Cdc6 phosphodegron for Cdc4. (A) GAL-CDC6-HA strains with various mutations (Δ370Δ371, Δ370, T370A, 
or T371A) were incubated in raffinose-containing medium and transferred to galactose-containing medium for 2 h to 
induce Cdc6 expression, and then cells were blocked with nocodazole. Cdc6 expression was suppressed by adding 
glucose. Protein samples were collected every 5 min and subjected to Western blot analysis to observe Cdc6-HA. Pgk1 
was used as a loading control. Western blotting images were quantified. Results represent the average of three 
experiments, with error bars indicating SD. (B) Yeast two-hybrid analysis was performed to determine the binding 
between Cdc4p and the Cdc6p C-terminus. Full-length CDC4 in the pACT plasmid, containing the GAL4 activation 
domain (GAD), was cotransformed into L40 yeast strains along with the various CDC6 mutants in the pBTM116 plasmid 
fused to LexA. Transformants were assayed for β-galactosidase activity, as visualized in blue. Proteins were extracted 
from each strain (1–4), and Cdc6 protein levels were examined by Western blotting.
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that Cdc6 degradation after DNA damage was mediated by Mck1 
kinase. We also observed suppression of Cdc6 degradation in the 
CDC6-T368A mutant, in which T368A mutation was integrated at 
the endogenous locus (Figure 4C). We conclude that DNA dam-
age triggers Mck1-dependent Cdc6 degradation.
Cdc6 degradation is mediated by the SCFCdc4 complex (Drury 
et al., 1997; Elsasser et al., 1999; Perkins et al., 2001). We found that 
MMS-induced Cdc6 degradation was suppressed when Cdc4 was 
defective (Figure 5A). Most likely, Cdc6 phosphorylations upon 
(Hall et al., 2007). We tested the possibility that DNA damage–in-
duced Cdc6 degradation is dependent on Mck1 kinase. Cdc6p 
from the endogenous promoter was degraded after MMS treat-
ment, as previously reported (Figure 4A; Hall et al., 2007), whereas 
Orc6 and Mck1 protein levels remained stable (Figure 4B). This 
suggests that MMS-induced protein degradation is specific to 
Cdc6p and is not indicative of an overall reduction in replication 
protein or general protein levels. The MMS-dependent Cdc6 deg-
radation was suppressed in Δmck1 cells (Figure 4A), suggesting 
FIGURE 4: DNA damage triggers Cdc6 degradation in Mck1-dependent manner. (A) CDC6-prA or Δmck1 CDC6-prA 
cells were incubated in yeast extract/peptone/dextrose (YEPD) medium to log phase, and then MMS was added (0.05% 
final). Protein extracts were made at 0-, 30-, or 60-min incubation and subjected to Western blotting to visualize 
endogenous Cdc6-prA. Pgk1 was used as a loading control. The same experiment was repeated three times to quantify 
Cdc6 protein levels. Average percentage of Cdc6p remaining is shown. Bars represent SD. (B) Protein degradation of 
Orc6-prA or Mck1-9MYC was examined by the same method using IgG or anti-MYC antibodies, respectively.  
(C) CDC6-prA or CDC6-T368A-prA cells were grown in YEPD to log phase. MMS at 0.1% concentration was added, 
and protein samples were collected after 0, 30, and 60 min. The protein extracts were subjected to Western blotting to 
visualize Cdc6-prA. The same experiment was performed three times. Cdc6 protein levels were quantified, and average 
percentage of Cdc6p remaining is shown. Bars represent SD.
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DISCUSSION
The mechanism of Cdc6 protein degradation is complex. Cdk1-
dependent Cdc6 phosphorylations and degradations have been 
extensively studied in order to understand the molecular mecha-
nism of Cdc6 control. The Cdc6 phosphorylation sites have been 
studied based on the CDK consensus motif ST or TP (Drury et al., 
2000; Perkins et al., 2001; Boronat and Campbell, 2007; Honey and 
Futcher, 2007). There are two GSK-3 consensus sites in Cdc6 (Figure 
1A). Both of the GSK-3 sites in Cdc6 overlap with two CDK consen-
sus sites; the second of each CDK site, at S43 or S372, is conserved, 
as it contains a lysine at the fourth position, K46 and K375, respec-
tively (Figure 1A). In this study, we found that the phosphorylation 
site at T368 in Cdc6, which was previously studied as a CDK site, is 
actually a GSK-3 phosphorylation site (Figure 2). GSK-3 kinase re-
quires priming phosphorylation (Lee et al., 2012; Lyons et al., 2013). 
Therefore we hypothesized that within the GSK-3 consensus site in 
Cdc6p (368TPTTS372), S372 would serve as the priming site for T368 
phosphorylation by Mck1 (Ikui et al., 2012). Because S372 occurs 
within a conserved Cdk1 site (T/SPxR/K), we predicted that Cdk1 
would provide this priming phosphorylation (Ikui et al., 2012). We 
showed that T368 is phosphorylated by Mck1 (Figure 2A). The 
Cdc6-S372 site, followed by a basic residue at the fourth position, 
was efficiently phosphorylated by Clb2/Cdk to serve as the priming 
phosphorylation site. Mck1 also phosphorylated the Cdc6 N-termi-
nal GSK-3 consensus site at T39, but with less efficiency (Figure 2A). 
We also tested the possibility that Clb2/Cdk1 phosphorylates S43, 
the other conserved CDK site, but we determined that it did not 
(unpublished data). It is possible that G1 cyclins or S-phase cyclins 
coupled with Cdk1 may phosphorylate the S43 site. This would al-
low cell cycle–dependent Cdc6 degradation whose timing relies on 
Cdk1-priming.
The GSK-3 consensus sequence, S/T-x-x-x-S/T, contains three 
amino acids between the priming and phosphorylation sites. To-
gether, they create a phosphodegron for SCFCdc4-dependent ubiq-
uitination (Ikui et al., 2012; Lyons et al., 2013). The GSK-3 sites at the 
N-terminus and C-terminus of Cdc6 coincide with a binding site for 
the Cdc4 E3 ubiquitin ligase (Perkins et al., 2001). It was shown that 
the protein binding between Cdc4 and Cdc6 is abolished when 
there is a mutation at T368 or S372 (Perkins et al., 2001). Here we 
show that the double phosphorylations created by Cdk1 at S372 
and Mck1 at T368 serve as a phosphodegron for Cdc4 binding. The 
spacing of two or three, and not one, amino acids between the two 
phosphorylations is important for Cdc4 recognition (Figure 3B). This 
is consistent with a previous report for Eco1p (Lyons et al., 2013). 
Mck1 requires a priming phosphorylation. For example, Eco1 must 
be primed by Dbf4 and Cdk1 for cohesion function regulation 
(Lyons et al., 2013) and Rpc53 must be primed by Kns1 in the TOR 
signaling pathway before Mck1 can phosphorylate either substrate 
(Lee et al., 2012). Possibly, Mck1 substrates are favored targets of 
Cdc4 (Mizunuma et al., 2001; Kishi et al., 2007; Ikui et al., 2012; 
Lyons et al., 2013; Edenberg et al., 2014), because the GSK-3 con-
sensus motif and the priming model can determine precise Cdc4 
specificity. These reports, together with our findings, strongly sug-
gest that there might be more GSK-3 substrates that are targeted in 
a Cdc4-dependent manner.
The presence of a separate Mck1-dependent degradation 
mechanism of Cdc6 raised the question of why such a mechanism is 
needed. First, we tested whether Mck1 is regulated in a cell cycle–
dependent manner. Mck1 protein was stable throughout the cell 
cycle, as were its localization and kinase activities (Supplemental 
Figure S5). Mck1 was shown to promote protein degradation in re-
sponse to stress (Andoh et al., 2000). We therefore reasoned that 
DNA damage are recognized by the SCFCdc4 complex for subse-
quent Cdc6p ubiquitination. It is known that Cdc6 degradation is 
also mediated through Tom1 and Dia2 (Hall et al., 2007; Kim et al, 
2012). We further tested whether Cdc6 degradation upon MMS 
treatment is mediated by the Tom1 or Dia2 ubiquitin ligases. We did 
not observe significant difference in Cdc6 degradation rate be-
tween wild-type, Δdia2, or Δtom1 deletion cells after MMS treatment 
(Supplemental Figure S3).
Cells with stabilized Cdc6 are susceptible to DNA damage
The homologous recombination protein Rad52 localizes to sites of 
double-stranded DNA breaks (DSBs) (Lisby et al., 2001). MMS in-
creases the frequency of DSBs in budded cells, as detected by the 
formation of Rad52-YFP foci (Lisby et al., 2003), likely due to an in-
creased frequency of replication fork collapse (Tercero and Diffley, 
2001). To test the functional significance of Mck1-mediated Cdc6 
degradation during DNA damage stress, we counted the frequency 
of Rad52-YFP foci in wild-type cells or Δmck1 cells after MMS treat-
ment. In unbudded cells during G1 phase, we did not observe a 
significant difference in the frequency of Rad52-YFP foci between 
wild-type and Δmck1 cells after MMS treatment (Figure 5B). Consis-
tent with previous work, however, more Rad52-YFP foci were formed 
in wild-type budded cells, both with and without MMS treatment 
(Figure 5B; Lisby et al., 2003). In untreated Δmck1 cells, we ob-
served a statistically higher rate of Rad52–yellow fluorescent protein 
(YFP) foci formation (Figure 5B). The Rad52-YFP foci frequency was 
increased after MMS treatment in both wild-type and Δmck1 cells, 
but more strikingly in Δmck1 cells (Figure 5B). Furthermore, cells 
expressing GAL-CDC6-T368A, which contains a mutation at the 
Mck1 phosphorylation site, had an increase in the frequency of 
Rad52-YFP foci formation after MMS treatment when grown in ga-
lactose-containing but not glucose-containing media compared 
with GAL-CDC6 cells (Figure 5C).
We further obtained evidence that the Cdc6-T368 site is more 
phosphorylated after MMS treatment (Figure 5D). This result sup-
ports our conclusion that Cdc6 is degraded after phosphorylation 
at the T368 site through Mck1 kinase. To test whether Mck1 has a 
role in preventing lethality in response to DNA damage, we tested 
cell viability of Δmck1 cells in MMS. The Δmck1 cells were not sen-
sitive to MMS, indicating that cell viability of Δmck1 was main-
tained due to DNA damage checkpoint activation in the presence 
of MMS (Figure 5E). We therefore tested whether deletion of a 
DNA damage checkpoint component may enhance lethality in 
Δmck1 cells. Deleting both MRE11 (a part of the MRX complex) 
and MCK1 genes enhanced lethality in response to MMS (Figure 
5E). Furthermore, a combination of Δmre11 and the GAL-CDC6-
T368A mutation also enhanced the cell lethality to MMS (Figure 
5E), supporting the idea that DNA damage in Δmck1 or GAL-
CDC6-T368A cells is augmented when a DNA checkpoint compo-
nent is eliminated.
We next tested whether the endogenous CDC6-T368A mutation 
behaves in the same way as GAL-CDC6-T368A. The CDC6-T368A 
cells did not show significant MMS sensitivity, similar to Δmck1 
(Figure 5F). Furthermore, Δmre11 CDC6-T368A double mutant did 
not have a significant difference in viability in response to MMS 
compared with Δmre11 (Figure 5F). We created CDC6-T39A,T368A, 
in which both mutations were integrated into the endogenous locus. 
CDC6-T39A,T368A cells did not show MMS sensitivity (Figure 5F). 
However, deleting MRE11 in CDC6-T39A,T368A cells enhanced le-
thality, similar to Δmck1 Δmre11 (Figure 5F). Furthermore, there was 
increased Rad52 foci formation in budded cells with endogenous 
CDC6-T39A,T368A after MMS exposure (Supplemental Figure S4).
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FIGURE 5: Cdc6 degradation upon DNA damage is mediated through the ubiquitin pathway. (A) CDC6-prA or cdc4-1 
CDC6-prA cells under the endogenous promoter were grown to log phase at 26°C first and then the temperature was 
increased to 36°C for 1.5 h. Then MMS was added (0.1% final). Samples were collected after 0, 30, or 60 min. The same 
experiment was performed three times, and Cdc6 protein levels were quantified. Error bars represent SD. (B) RAD52-
YFP or Δmck1 RAD52-YFP cells were grown to log phase in low-fluorescence medium. MMS was added (0.05% final) for 
90 min. Rad52-YFP foci were visualized under a fluorescence microscope to assay for double-stranded DNA breaks 
before and after treatment with MMS. Percentage of cells containing Rad52 foci was determined in unbudded or 
budded cells. One hundred cells were counted for each sample. Percentage is average from three independent 
experiments, and error bars represent the SD. *p < 0.05. (C) GAL-CDC6 or GAL-CDC6-T368A cells were grown to 
log phase in raffinose-containing medium first, and then either glucose or galactose was added for 3 h of incubation. 
Finally, MMS was then added (0.05% final) for 1 h. Rad52-YFP foci formation was determined with or without MMS 
Volume 26 July 15, 2015 Cdc6 regulation by CDK and GSK-3 | 2617 
Mck1 under DNA damage stress ensures genome integrity and 
maintenance of proper cell proliferation. We also observed that 
overexpression of CDC6 but not the CDC6-T368A mutant partially 
rescues MMS sensitivity in the mre11-deletion strain (Figure 5E, bot-
tom). Mcm complex plays a role in the DNA damage–induced sig-
naling that controls DNA replication (Cortez et al., 2004). Overex-
pression of Cdc6 helps Mcm complex to be loaded on DNA (Frigola 
et al., 2013), which may enhance the DNA damage signaling path-
way to rescue the Δmre11 lethality to MMS.
In humans, deregulation of replication factors, such as Cdc6, has 
been observed in many cancers. For instance, Cdc6 overexpression 
has been associated with brain tumors (Ohta et al., 2001), cervical 
cancer (Murphy et al., 2005), and lung carcinomas (Karakaidos et al., 
2004). Given the implication of Cdc6 up-regulation in human can-
cers (Borlado and Mendez, 2008), it would be of considerable inter-
est to study whether mammalian GSK-3 kinase plays a role in Cdc6 
degradation. Cdc6 degradation during alkylating DNA damage is 
conserved between humans and yeasts (Hall et al., 2007). Therefore 
it is possible that human GSK-3 kinase, similar to Mck1, might pro-
mote Cdc6 degradation. A link between mammalian GSK-3 kinase 
and the DNA damage response has been reported. GSK-3 kinase 
phosphorylates the oncogenic metazoan transcription factor c-Myc 
after DNA damage triggered by ultraviolet light. The phosphory-
lated c-Myc is targeted for ubiquitination by SCFFbw7, the human 
homologue of Cdc4 (Popov et al., 2007). Of interest, c-Myc was 
shown to have a nontranscriptional role in the initiation of DNA rep-
lication (Dominguez-Sola et al., 2007). Although it is not clear 
whether the c-Myc degradation during DNA damage is associated 
with the replication function of c-Myc, it would support the general 
idea that DNA replication is inhibited during DNA damage through 
degradation of replication proteins.
MATERIALS AND METHODS
Plasmids and strains
Standard methods were used for mating, tetrad dissection, and trans-
formation. All strains listed in Supplemental Table S1 are congenic 
with W303. p305-based GAL-CDC6-HA plasmid was a gift from Ste-
phen P. Bell (Massachusetts Institute of Technology, Cambridge, MA). 
GAL-CDC6-HA strains were made as described previously (Wilmes 
et al., 2004). Briefly, GAL-CDC6-HA plasmid was linearized with StuI 
and integrated at the URA locus in the wild-type strain. The copy 
number of the integrated GAL-CDC6 was determined by real-time 
PCR. GAL-CDC6 mutations were made by site-directed mutagenesis 
(QuikChange II XL mutagenesis kit; Agilent, Santa Clara, CA) using 
the GAL-CDC6-HA plasmid as a template. The mutagenized GAL-
CDC6 plasmid was integrated at the URA locus in wild-type cells, and 
the copy number was determined as described. MCK1-9MYC strain 
was constructed as described previously (Knop et al., 1999). CDC6-
T368A and CDC6-T39A,T368A strains were generated by two-step 
PCR in order to integrate the mutation into the genomic locus 
(Figures 4C and 5F; Toulmay and Schneiter, 2006).
the Mck1-dependent Cdc6p degradation could be involved in the 
cell’s response to stress. The Cdc6 degradation in response to MMS 
was dependent on Mck1 kinase (Figure 4, A and C). Furthermore, 
MMS-induced Cdc6 degradation was mediated through SCF F-box 
protein (Cdc4) (Figure 5A). The continuous Mck1 activity throughout 
the cell cycle may help to phosphorylate and degrade Cdc6p when 
cells are exposed to DNA damage agent.
We also tested whether hydroxyurea (HU) or benomyl promotes 
Cdc6 degradation, since Δmck1-deletion cells are sensitive to these 
reagents (Shero and Hieter, 1991). However, Cdc6 was stable after 
HU or benomyl treatment (Supplemental Figure S6). These results 
indicate that Mck1-dependent Cdc6 degradation is triggered by 
specific DNA damage through alkylating agents. It has been re-
ported that Sld3 is phosphorylated and inhibits late origin firing 
when cells are treated with MMS (Lopez-Mosqueda et al., 2010; 
Zegerman and Diffley, 2010). The inhibition of late origin firing is 
dependent on Rad53 (Lopez-Mosqueda et al., 2010; Zegerman and 
Diffley, 2010). Mck1-dependent Cdc6 degradation may serve as an 
additional mechanism to block origin firing, and it would be of inter-
est to know whether the Mck1-dependent mechanism inhibits early 
and/or late origin firing. It remains to be investigated whether Mck1 
is activated upon DNA damage directly. We observed that Cdc6 is 
more stabilized in CDC6-T368A than in Δmck1 (Figure 1B). This re-
sult raised the possibility that Cdc6p may be phosphorylated 
through another kinase, such as Rad53 or Mec1.
Cells undergoing S phase are more prone to DNA damage by 
MMS (Lisby et al., 2003). We also observed that Δmck1 cells accu-
mulate more DNA damage in budded cells, which includes S-phase 
cells, than in wild-type cells (Figure 5C). We conclude that DNA rep-
lication has to be controlled and inhibited in early S phase by inhibit-
ing Cdc6p so that cells do not proceed through S phase when cells 
are exposed to DNA damage agents. Continuous initiation of DNA 
replication during S phase under DNA damage stress will lead to 
accumulation of DNA damage and lethality.
It will be also interesting to identify novel Mck1 substrates. We 
searched for proteins that contain a GSK-3 consensus motif simi-
lar to that in Cdc6, S/T-P-X-X-S/T-P-X-R/K. Using the MOTIF 
search database (www.genome.jp/tools/motif/MOTIF2.html), we 
identified 17 candidate proteins that contain a similar GSK-3 con-
sensus sequence, including three DNA replication proteins, Cdc6, 
Mcm3, and Sld2. Although we do not yet have evidence that 
Mck1 targets these proteins, it would be interesting to study 
whether Mck1 targets other proteins besides Cdc6p.
The Δmck1 cells are not sensitive to MMS (Figure 5E), which sug-
gests that the DNA damage checkpoint might be activated and pro-
tects Δmck1 cells even after the accumulation of DNA damage. De-
letion of a DNA damage checkpoint gene enhanced Δmck1 
sensitivity to MMS, supporting the hypothesis (Figure 5E). Desany 
et al. (1998) reported that overexpression of MCK1 suppresses le-
thality in rad53 mutants, indicating that Mck1p has a role in DNA 
damage repair. We propose a model in which Cdc6 inhibition by 
treatment. One hundred cells were counted for each sample. Percentage is average from three independent 
experiments, and error bars represent SD. (D) cdc4-1 GAL-CDC6-HA cells were incubated in raffinose-containing 
medium first. Galactose was then added for 1 h of incubation, followed by nocodazole for 1.5 h. The temperature was 
then raised to 36°C to inactivate Cdc4 function for 1.5 h. Finally, cells were treated with MMS (0.1% final) and sampled 
every 30 min. Western blotting was performed using anti-phosphoT368 of Cdc6 and anti-HA. Control experiment was 
performed in raffinose-containing medium, indicated as “pre.” (E, F) Cells with indicated genotypes were serially diluted 
10-fold on yeast extract/peptone/dextrose or yeast extract/peptone/galactose plates containing 0.002% MMS. The 
plates were incubated at 30°C for 2 d.
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mine the budding of the cells. Log-phase MCK1-GFP cells were 
lightly fixed in 4% paraformaldehyde and then stained with DAPI. 
The fixed cells were imaged using the relevant wavelengths, and the 
images were pseudocolored and processed using ImageJ.
Yeast two-hybrid assay
The pBTM116 constructs containing Cdc6 is a generous gift from J. 
Diffley’s lab (Francis Crick Institute, London, UK; Perkins et al., 2001). 
The CDC6-pBTM116 plasmid was subjected to site-directed muta-
genesis to create the various Cdc6 mutants (QuikChange Lightning 
Kit; Agilent). The CDC4/pACT plasmid and each of the various 
CDC6/pBMT116 plasmids were cotransformed into L40 strain and 
plated on synthetic defined-Leu/Trp plates, and β-galactosidase ac-
tivity was measured as described previously (Ikui et al., 2012).
Cell cycle block experiments
Mitotic cell cycle arrest was achieved using 15 μg/ml nocodazole for 
2 h at 30°C. GAL-CDC6–HA strains were grown to log phase in me-
dium containing 3% raffinose. Galactose was then added to induce 
CDC6-HA expression for 2 h, followed by incubation in nocodazole 
for another 2 h. Glucose was then added to shut off the expression. 
For the α-factor arrest experiments, log-phase cells were arrested in 
G1 using 100 nM α-factor for 2 h at 30°C.
Western blotting
Cells were lysed by agitation in SDS sample buffer with glass beads 
using FastPrep (MP Biomedicals, Santa Ana, CA) for 20 s, twice, at 
speed 6. Proteins were separated by SDS–PAGE with 10% polyacryl-
amide gel, except for the samples in Figure 2, which were separated 
using SDS–PAGE with Novex 4–20% Tris-glycine polyacrylamide gel 
(Invitrogen, Life Technologies, Carlsbad, CA). Western blot analysis 
was performed using anti-hemagglutinin (HA) antibody 3F10 
(Roche, Penzberg, Germany) at 1:2000 dilution, anti-Clb2 antibody 
(a generous gift from Frederick Cross, Rockefeller University, New 
York, NY), anti–phospho Cdc6-T368 antibody at 1:1000 dilution 
(custom-made antibody by 21st Century Bio, Marlboro, MA), anti-
cMYC antibody 9E10 (Sigma-Aldrich, St. Louis, MO) at 1:2000 dilu-
tion, and anti-Pgk1 (Life Technologies, Carlsbad, CA) at 1:2000 as a 
loading control. Protein A–tagged proteins were probed using 
horseradish peroxidase–conjugated anti-rabbit immunoglobulin G 
(Sigma-Aldrich) at 1:5000.
To detect phospho–Cdc6-T368, CDC6 was immunoprecipitated 
by HA-affinity purification first in order to enhance the signal (Ikui 
et al., 2012).
Kinase assay
Clb2-Cdk1 and Mck1 proteins were purified from yeast cells express-
ing TAP-tagged proteins as previously described (Lyons and Morgan, 
2011). The TAP-tagged plasmid for Clb2 and Mck1 were kindly pro-
vided by David O Morgan (University of California, San Francisco, 
San Francisco, CA; Lyons et al., 2013). Peptide kinase assay was per-
formed as described (Lyons et al., 2013) at room temperature for 30 
min using purified Mck1 or Clb2-Cdk1 with 5 μM peptides (synthe-
sized by NeoBioLab, Woburn, MA) in a 15-μl total reaction, with 0.6 
μCi of [γ-32P]ATP (3000 μCi mmol−1; PerkinElmer, Melville, NY). After 
stopping the reaction and washing, radioactivity was measured using 
a scintillation counter (Tri-Carb 2800; PerkinElmer; Puig et al., 2001).
Microscope
Cells were grown in low-fluorescence medium, which was prepared 
as described previously (Sheff and Thorn, 2004). Cells were imaged 
on an Eclipse 90i microscope (Nikon, Tokyo, Japan) with a total inter-
nal reflection fluorescence 60×/1.45 numerical aperture Plan Apo-
chromatic objective lens (Nikon) fitted with a cooled Clara interline 
charge-coupled device camera (Andor, Belfast, United Kingdom) 
and using an Intensilight Ultra High Pressure 130-W mercury lamp 
(Nikon) as an illumination source. Images were acquired using the 
NIS Element BR software (Nikon). Image acquisition times for green 
fluorescent protein, YFP, 4′,6-diamidino-2-phenylindole (DAPI), and 
differential interference contrast (DIC) were 300, 200, 50, and 50 ms, 
respectively. All images were processed using ImageJ software (Na-
tional Institutes of Health, Bethesda, MD; Schneider et al., 2012). To 
visualize RAD52-YFP foci, the DIC image was acquired, followed by 
seven YFP images at 0.5-μm intervals along the z-axis. YFP image 
stacks were combined through maximum intensity projection in or-
der to count Rad52-YFP foci along the entire z-stack for each field. 
The corresponding DIC images were used as a reference to deter-
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